Key Content
Find It targets genomic content associated with approved therapies, treatment resistance, disease prognosis, and clinical trials.
Find It focuses on gene mutations that can be addressed by current FDA-approved therapies.
Find It is more than an assay: it’s a complete solution. Imagia Canexia Health partners leverage our expert end-to-end support and proprietary technology as well as a focused panel that identifies therapeutic targets for patients, acquired drug resistance mutations, and mutations with prognostic and diagnostic implications for care.
Find It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 37 known cancer-associated genes simultaneously.
Find It detects indications for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.
Gene | Position |
---|---|
AKT1 | E17 |
ALK | T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278 |
AR | L702, V716, S741, W742, Q784, H875, F877, T878, M896 |
BRAF | Q201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, part of Exon15 (V600-M620), G606 |
CCNE | Amplification |
CTNNB1 | D32, S33, G34, I35, H36, S37, T41, S45 |
DDR2 | L239, I638, S768 |
DICER1 | D1705-D1709, G1809, D1810-E1813 |
EGFR | R108, A289, S492, P596, G598, Exon18, Exon19, Exon20, Exon21, & Amplification |
ERBB2 | G309, S310, K753, L755, I767, D769, Exon20, & Amplification |
ESR1 | K303, E380, S463, V534, P535, L536, Y537, D538 |
FGFR1 | N546, K656, & Amplification |
FGFR2 | S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification |
FGFR3 | R248, S249, G370, S371, Y373, G380, A391, K650 |
FOXL2 | C134 |
GNA11 | Q209 |
GNAQ | Q209 |
GNAS | R201 |
HRAS | G12, G13, Q61 |
IDH1 | R132 |
IDH2 | R140, R172 |
KIT | S476, Y553, W557,, V559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Exon9, Exon11, Exon13, & Amplification |
KRAS | K5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification |
MAP2K1(MEK1) | F53, Q56, K57, K59, V60, D67, I103, I111, C121, N122, P124, P387 |
MAP2K2(MEK2) | F57, Q60, K61, L119, H123, G132 |
MET | T1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Exon13, Exon14, Exon14 (-50 to+25), Exon18, Amplification |
NRAS | G12, G13, A59, G60, Q61, K117, A146 |
NTRK1 | F589, G595, G667 |
NTRK3 | G623, G696 |
PDGFRA | R560-E571, P577, N659, L839-Y849, D842 |
PIK3CA | R88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Exon6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049 + Amplification |
POLE | Exons 9-14 (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F) |
PTCH1 | W844, G1093 |
PTEN | A126, G129, R130, R173, R233, K254-K267 |
RET | G533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791, V804, Y806, A883, R886, S904, M918, A919, Exon10, Exon 13, Exon15 |
ROS1 | S1986, G2032, L2026 |
STK11 | Q37, P281 |
TP53 | Exon4, Exon5, Exon6, Exon7, Exon8, Exon9 |
MSI | 21 Loci |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
PTCH1 oncogenic mutations | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
AKT1 E17K | IB | ||
ERBB2 amplification | IA | ||
ERBB2 oncogenic mutations | IB | ||
ESR1 oncogenic mutations | IB | ||
FGFR1 amplification | IIC | ||
PIK3CA oncogenic mutations | IA | ||
MSI-H | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
BRAF V600E | IA | ||
ERBB2 Amplification | IA/IB | ||
KRAS wild type | IA | ||
KRAS and NRAS wild-type | IA | ||
KRAS and NRAS oncogenic mutations | IA | ||
MSI | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
ERBB2 Amplification | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
ERBB2 Amplification | IA | ||
MSI | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
KIT oncogenic mutations | IA/IID | ||
KIT A829, D816, D820, N822, T670, V654, Y823 | IID | ||
KIT V654 | IID | ||
PDGFRA oncogenic mutations | IA | ||
PDGFRA D842 | IA |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
ALK oncogenic mutations | IA/IID | ||
BRAF V600E | IA | ||
EGFR G719 (exon 18), exon 19 deletions, S768I (exon 20), L858R, L861Q (exon21) | IA | ||
EGFR exon 19 deletions, L858R (exon 21) | IA | ||
EGFR exon 20 insertion, T790M (exon 20) | IA | ||
EGFR T790M (exon 20), L858R (exon 21) | IA | ||
EGFR C797, L718, L792, G796 | IID | ||
EGFR exon 20 insertion | IA | ||
EGFR exon 18 indel | IB | ||
EGFR exon 19 insertion | IB | ||
EGFR exon 19 & 20 insertion, L747 | IID | ||
ERBB2 oncogenic mutations | IA | ||
KRAS G12C | IA | ||
MAP2K1 oncogenic mutations | IB | ||
MET exon 14 skipping | IA | ||
MET amplification | IA/IID |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
BRAF V600 | IA | ||
BRAF V600E | IA | ||
BRAF V600K | IA | ||
BRAF L597, V601 | IB | ||
KIT oncogenic mutations | IA | ||
MAP2K1 oncogenic mutations | IB | ||
NRAS oncogenic mutations | IB/IID |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
FGFR3 R248C, S249C, G370C, Y373C | IA | ||
FGFR3 S371C, G380R, K650 | IB | ||
HRAS oncogenic mutuations | IB |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
BRAF G464, G469, L597, K601 | IID | ||
FGFR1, FGFR2, FGFR3 oncogenic mutations | IID | ||
KRAS oncogenic mutations | IID | ||
Microsatellite Instability-High (MSI-H) | IA | ||
NTRK1 and NTRK3 mutations | IA | ||
NTRK1 G595R | IID | ||
PTEN oncogenic mutations | IID |
Biomarkers detected by Find It® | Available FDA Approved Therapy | AMP/ASCO/CAP Tier* | Resistance |
---|---|---|---|
AKT1 E17K | IB | ||
CCNE1 Amplification | IID | ||
MAP2K1 oncogenic mutations | IB |
Genes | 38 |
---|---|
Hotspots | 337 |
Exons | 26 |
Turnaround Time | 3-5 days |
Mutation types | SNVs, deletions and insertions(up to 24bp), CNVs and MSI |
Sample Type | Scrolls/curls & unstained slides |
Sample Requirement | Sample requirements are the same if you are ordering just Find It, just Fusions, or both assays. Please include one H&E slide or a digital image (to test@imagiacanexiahealth.com) from the same FFPE block, including the circled tumour area. Please complete specimen details on the TRF including the % tumour content. |
Find It targets genomic content associated with approved therapies, treatment resistance, disease prognosis, and clinical trials.
A simple laboratory workflow that provides rapid, reliable, results.
Automated reporting from the Imagia Canexia Health Insights Platform provides up-to-date information on interpretations, current treatment options, and available clinical trials.
Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.
Find It and Fusions single sample panels allows for simultaneous hotspot testing, reducing the amount of biopsy tissue required.
All Imagia Canexia Health assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.
Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.
Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.
From mutation identification to auto-generated reports, Imagia Canexia Health’s proprietary platform allows you to perform mutation assay for cancer right from your laboratory.
Clinical Services can support your local lab bring precision oncology testing in-house.